Conventional MRI Criteria to Differentiate Progressive Disease From Treatment-Induced Effects in High-Grade (WHO Grade 3-4) Gliomas

被引:6
作者
Flies, Christina M. [1 ]
van Leuken, Karlijn H. [1 ,5 ]
ten Voorde, Marlies [1 ,6 ]
Verhoeff, Joost J. C. [2 ]
De Vos, Filip Y. F. [3 ]
Seute, Tatjana [1 ]
Robe, Pierre A. [1 ]
Witkamp, Theodoor D. [4 ]
Hendrikse, Jeroen [4 ]
Dankbaar, Jan Willem [4 ]
Snijders, Tom J. [1 ]
机构
[1] Univ Med Ctr Utrecht, Dept Neurol & Neurosurg, UMC Utrecht Brain Ctr, Utrecht, Netherlands
[2] Univ Med Ctr Utrecht, Dept Radiat Oncol, Utrecht, Netherlands
[3] Univ Med Ctr Utrecht, Dept Med Oncol, Utrecht, Netherlands
[4] Univ Med Ctr Utrecht, Dept Radiol, Utrecht, Netherlands
[5] Stichting Beroepsopleiding Huisarts, Utrecht, Netherlands
[6] Misson Netherlands Reformed Congregat Guinea, Siguiri, Guinea
关键词
CEREBRAL RADIATION NECROSIS; CENTRAL-NERVOUS-SYSTEM; RESPONSE ASSESSMENT; TUMOR RECURRENCE; PSEUDOPROGRESSION; GLIOBLASTOMA; CONCOMITANT; THERAPY; BRAIN; CHEMOTHERAPY;
D O I
10.1212/WNL.0000000000200359
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Objectives Posttreatment radiologic deterioration of an irradiated high-grade (WHO grade 3-4) glioma (HGG) may be the result of true progressive disease or treatment-induced effects (TIE). Differentiation between these entities is of great importance but remains a diagnostic challenge. This study assesses the diagnostic value of conventional MRI characteristics to differentiate progressive disease from TIE in HGGs. Methods In this single-center, retrospective, consecutive cohort study, we included adults with a HGG who were treated with (chemo-)radiotherapy and subsequently developed a new or increasing contrast-enhancing lesion on conventional follow-up MRI. TIE and progressive disease were defined radiologically as stable/decreased for >= 6 weeks or Response Assessment in Neuro-Oncology progression and histologically as TIE without viable tumor or progressive disease. Two neuroradiologists assessed 21 preselected MRI characteristics of the progressive lesions. The statistical analysis included logistic regression to develop a full multivariable model, a diagnostic model with model reduction, and a Cohen kappa interrater reliability (IRR) coefficient. Results A total of 210 patients (median age 61 years, interquartile range 54-68, 189 male) with 284 lesions were included, of whom 141 (50%) had progressive disease. Median time to progressive disease was 2 (0.7-6.1) and to TIE 0.9 (0.7-3.5) months after radiotherapy. After multivariable modeling and model reduction, the following determinants prevailed: radiation dose (odds ratio [OR] 0.68, 95% CI 0.49-0.93), longer time to progression (TTP; OR 3.56, 95% CI 1.84-6.88), marginal enhancement (OR 2.04, 95% CI 1.09-3.83), soap bubble enhancement (OR 2.63, 95% CI 1.39-4.98), and isointense apparent diffusion coefficient (ADC) signal (OR 2.11, 95% CI 1.05-4.24). ORs >1 indicate higher odds of progressive disease. The Hosmer & Lemeshow test showed good calibration (p = 0.947) and the area under the receiver operating characteristic curve was 0.722 (95% CI 0.66-0.78). In the glioblastoma subgroup, TTP, marginal enhancement, and ADC signal were significant. IRR analysis between neuroradiologists revealed moderate to near perfect agreement for the predictive items but poor agreement for others. Discussion Several characteristics from conventional MRI are significant predictors for the discrimination between progressive disease and TIE. However, IRR was variable. Conventional MRI characteristics from this study should be incorporated into a multimodal diagnostic model with advanced imaging techniques. Classification of Evidence This study provides Class II evidence that in patients with irradiated HGGs, radiation dose, longer TTP, marginal enhancement, soap bubble enhancement, and isointense ADC signal distinguish progressive disease from TIE.
引用
收藏
页码:E77 / E88
页数:12
相关论文
共 33 条
[11]   Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment [J].
Kumar, AJ ;
Leeds, NE ;
Fuller, GN ;
Van Tassel, P ;
Maor, MH ;
Sawaya, RE ;
Levin, VA .
RADIOLOGY, 2000, 217 (02) :377-384
[12]   The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary [J].
Louis, David N. ;
Perry, Arie ;
Reifenberger, Guido ;
von Deimling, Andreas ;
Figarella-Branger, Dominique ;
Cavenee, Webster K. ;
Ohgaki, Hiroko ;
Wiestler, Otmar D. ;
Kleihues, Paul ;
Ellison, David W. .
ACTA NEUROPATHOLOGICA, 2016, 131 (06) :803-820
[13]   Neuroimaging Findings of the Post-Treatment Effects of Radiation and Chemotherapy of Malignant Primary Glial Neoplasms [J].
Mamlouk, M. D. ;
Handwerker, J. ;
Ospina, J. ;
Hasso, A. N. .
NEURORADIOLOGY JOURNAL, 2013, 26 (04) :396-412
[14]  
Mullins ME, 2005, AM J NEURORADIOL, V26, P1967
[15]   Response-driven imaging biomarkers for predicting radiation necrosis of the brain [J].
Nazem-Zadeh, Mohammad-Reza ;
Chapman, Christopher H. ;
Chenevert, Thomas ;
Lawrence, Theodore S. ;
Ten Haken, Randall K. ;
Tsien, Christina I. ;
Cao, Yue .
PHYSICS IN MEDICINE AND BIOLOGY, 2014, 59 (10) :2535-2547
[16]   CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016 [J].
Ostrom, Quinn T. ;
Cioffi, Gino ;
Gittleman, Haley ;
Patil, Nirav ;
Waite, Kristin ;
Kruchko, Carol ;
Barnholtz-Sloan, Jill S. .
NEURO-ONCOLOGY, 2019, 21 :V1-V100
[17]   MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis [J].
Patel, Praneil ;
Baradaran, Hediyeh ;
Delgado, Diana ;
Askin, Gulce ;
Christos, Paul ;
Tsiouris, Apostolos John ;
Gupta, Ajay .
NEURO-ONCOLOGY, 2017, 19 (01) :118-127
[18]   Cerebral radiation necrosis: A review of the pathobiology, diagnosis and management considerations [J].
Rahmathulla, Gazanfar ;
Marko, Nicholas F. ;
Weil, Robert J. .
JOURNAL OF CLINICAL NEUROSCIENCE, 2013, 20 (04) :485-502
[19]   Morphologic magnetic resonance imaging features of therapy-induced cerebral necrosis [J].
Rogers, L. R. ;
Gutierrez, J. ;
Scarpace, L. ;
Schultz, L. ;
Ryu, S. ;
Lord, B. ;
Movsas, B. ;
Honsowetz, J. ;
Jain, R. .
JOURNAL OF NEURO-ONCOLOGY, 2011, 101 (01) :25-32
[20]   Cerebral radiation necrosis: Incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy [J].
Ruben, Jeremy D. ;
Dally, Michael ;
Bailey, Michael ;
Smith, Robin ;
McLean, Catriona A. ;
Fedele, Pasqual .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 65 (02) :499-508